SLC43A3

Equilibrative nucleobase transporter 1 · Q8NBI5 · SLC43A3 on Sugi Atlas →

0 patent compounds predicted against SLC43A3, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to SLC43A3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Age on the Renal Clearance of Adefovir PHASE4WITHDRAWN
Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD PHASE3COMPLETED
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP) PHASE2COMPLETED
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia PHASE1/PHASE2COMPLETED
FET-PET for Evaluation of Response of Recurrent GBM to Avastin PHASE2COMPLETED
Influence of the OATP1B1 and OATP1B3 Genotype on the Hepatic Uptake of Primovist® PHASE1/PHASE2COMPLETED
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia PHASE1/PHASE2RECRUITING
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia PHASE2COMPLETED
Safety and Pharmacokinetic Profiles of Two Formulations of CO-1.01 in Patients With Advanced Solid Tumors PHASE1COMPLETED
PK Study of Oral and IV Clofarabine in High Risk Myelodysplasia+Acute Leukemias PHASE1COMPLETED
Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1 PHASE1COMPLETED
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors PHASE1COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime PHASE1COMPLETED
Pharmacokinetic Drug-Drug Interaction Study to Identify Biomarkers of Kidney Transporters EARLY_PHASE1COMPLETED
Gadoxetate Sodium Enhanced MRI as a Biomarker for Aggressive Prostate Cancer EARLY_PHASE1UNKNOWN
Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I EARLY_PHASE1COMPLETED
Impact of Polymorphisms of OAT1, OAT3, and OCT2 on Transportation of Potential Nephrotoxic Drugs nanCOMPLETED
Biomarker Directed Adjuvant Chemotherapy for Resected Pancreas Cancer nanUNKNOWN
Natural History Study of SLC25A46 Mutation-related Mitochondriopathy nanCOMPLETED
Oxalate and Citrate in Humans - Response to Citrate nanRECRUITING
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals nanENROLLING_BY_INVITATION
Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL nanCOMPLETED
Characterization of Breg Cells nanCOMPLETED
Impact of Genetics on Metformin Pharmacokinetics nanCOMPLETED
ADPKD Alterations in Hepatic Transporter Function nanCOMPLETED
Hyperlactacidemia in Major Abdominal Surgery and Monocarboxylate Receptors nanUNKNOWN
Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients nanUNKNOWN
Individualized Antiretroviral Therapy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a SLC43A3 binder may also engage these)

ProteinNameSimilarity
Q1JPD8 0.995 Q1JPD8 →
A2AVZ9 0.986 A2AVZ9 →
Q5EBA8 0.964 Q5EBA8 →
Q61124 0.963 Q61124 →
Q9I9R3 0.962 Q9I9R3 →
Q29611 0.960 Q29611 →
Q7ZWG6 0.959 Q7ZWG6 →
A1L272 0.957 A1L272 →
Q60HH0 0.956 Q60HH0 →
Q13286 0.956 Q13286 →
Q9BZV2 0.955 Q9BZV2 →
Q5U3U7 0.955 Q5U3U7 →
Q6GNV7 0.955 Q6GNV7 →
Q0VC03 0.954 Q0VC03 →
A4IH46 0.954 A4IH46 →
SLC19A2 Thiamine transporter 1 0.954 landscape →
Q640L2 0.954 Q640L2 →
Q6PEM8 0.954 Q6PEM8 →
Q8NA29 0.954 Q8NA29 →
Q4R877 0.953 Q4R877 →
Q5E9R1 0.953 Q5E9R1 →
D2HSA6 0.953 D2HSA6 →
Q4FZU9 0.952 Q4FZU9 →
Q569T7 0.952 Q569T7 →
Q05B81 0.951 Q05B81 →
Q923U9 0.951 Q923U9 →
Q6DCX5 0.951 Q6DCX5 →
Q6N075 0.950 Q6N075 →
Q9JHI9 0.950 Q9JHI9 →
Q921Y4 0.950 Q921Y4 →